Both GLP‐1 RAs and tirzepatide improve multiple cardiometabolic risk factors (waist circumference, systolic blood pressure, lipid profile) and quality of life parameters in people with obesity and/or diabetes [17]. The gene discussed is GCG; the disease is obesity disorder.